Client News

AFYREN Provides Business Update and Announces a €10 Million Sustainable Financing for its Subsidiary AFYREN NEOXY

Formycon and Fresenius Kabi Canada Receive Health Canada’s Approval for FYB202/Otulfi® (ustekinumab), a Biosimilar to Stelara®

ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial

QUANTRO Therapeutics Achieves Breakthrough in Transcriptomic Drug Discovery with First Successful Simultaneous 10-Target Multiplex-Screening

InflaRx Announces Participation in January Events in San Francisco

Abivax Announces a Change to the Composition of its Board of Directors

Galimedix Therapeutics Initiates Pivotal Phase 2 Study with GAL-101 Eye Drops in Dry AMD

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

iOmx Therapeutics Submits Clinical Trial Application for IOMX-0675